PlainPill

Creatine vs Pramiracetam for focus

Short answer: For focus, users rate them about the same: 93% report improvement with Creatine (249 reports) and 95% with Pramiracetam (91 reports).

Creatine has 763 meta-analyses and 2,794 randomized trials on PubMed; Pramiracetam has 0 and 3.

Based on 2,279 reports about Creatine and 343 about Pramiracetam. Not medical advice.

Creatine
Supplement
Pramiracetam
Supplement
Users say it helped72%helped1,048 reports · high confidence59%helped127 reports · high confidence
Verdict
Mostly positive
Mixed
ResearchAResearch: StrongCResearch: Limited
Meta-analyses / RCTs763 / 2,7940 / 3
Mainly used for
Performance
% reporting improvement
98% (542)—
Focus
% reporting improvement
93% (249)95% (91)
Energy
% reporting improvement
97% (268)91% (11)
Mood
% reporting improvement
87% (125)45% (22)
Memory
% reporting improvement
93% (85)95% (38)
Common side effectsstomach issues, hair loss, insomnia, water retentionheadache, emotional blunting, fatigue, bad taste
Typical dose reported5 g / daily1 teaspoon
Creatine
Latest review conclusion

The results of the meta-analysis suggest that creatine supplementation did not significantly alter serum creatinine levels (standardized mean difference = 0.48, 95% confidence interval 0.24-0.73, P = .001, I2 = 22%), and did not alter plasma urea values (standardized mean difference = 1.10, 95% confidence interval 0.34-1.85, P = .004, I2 = 28%). The findings indicate that creatine supplementation does not induce renal damage in the studied amounts and durations.

J Ren Nutr, 2019 ↗
What a user said
“I actually feel a lot better. Mentally clearer and more balanced, like I have my brain back.”
Full Creatine profile →
Pramiracetam
What a user said
“I was very anxious and listless for a while and the substances that helped me the most were Pramiracetam + alpha GPC.”
Full Pramiracetam profile →

Related comparisons

Percentages come from first-hand user reports and are not clinical outcomes. Talk to a doctor before starting, stopping or combining anything. How we rate